MedTrace Logo

Exoskeleton-assisted Training to Accelerate Walking Recovery Early After Stroke: the TARGET Phase II Study

NCT03727919 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-04-13

No results posted yet for this study

Summary

Phase II: Investigating the effects of additional robot-assisted gait training either initiated early (2 weeks post-stroke) or delayed (8 weeks post-stroke) after stroke onset.

Conditions

  • Stroke
  • Paresis
  • Gait, Hemiplegic

Interventions

BEHAVIORAL

Exoskeleton-assisted gait training

In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.

Sponsors & Collaborators

  • University Hospital, Antwerp

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Jonas Schröder, PhD Student · Dept. Rehabilitation Sciences & Physiotherapy, University of Antwerp, Belgium

  • Wim Saeys, Prof. Dr. · Dept. Rehabilitation Sciences & Physiotherapy, University of Antwerp, Belgium

  • Steven Truijen, Prof. Dr. · Dept. Rehabilitation Sciences & Physiotherapy, University of Antwerp, Belgium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2022-02-07
Completion
2022-02-07

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03727919 on ClinicalTrials.gov